Does the K153R variant of the myostatin gene influence the clinical presentation of women with McArdle disease?

dc.contributor.authorGonzález-Freire, Martaspa
dc.contributor.authorSantiago Dorrego, Catalina
dc.contributor.authorGómez Gallego, Félix
dc.contributor.authorPérez Ruiz, Margarita
dc.contributor.authorFoster, Carlspa
dc.contributor.authorArenas, Joaquínspa
dc.contributor.authorLucía Mulas, Alejandro
dc.date.accessioned2013-11-27T17:26:52Z
dc.date.available2013-11-27T17:26:52Z
dc.date.issued2009spa
dc.description.abstractThere is individual variability in the clinical manifestation of McArdle disease, with women generally being more severely affected than men. We compared clinical presentation and exercise capacity between (i) four women with McArdle disease (aged 17, 36, 42 and 70 years) who were also carriers of the K153R variant in the myostatin (GDF-8) gene and in (ii) four women with this disorder matched forage (16, 33, 40 and 69 years), lifestyle, and documented genotype modulators of this disease (ACE, AMPD1 and ACTN3), who did not carry the myostatin variant. Except in the youngest patient, clinical severity was higher in K153R carriers than in their K/K(2) controls (aged 33, 40 and 46 years). Peak cardiorespiratory capacity was very low (< or = 13 mLO(2)/kg/min) in all K153R carriers.spa
dc.description.filiationUEMspa
dc.description.impact2.977 JCR (2009) Q2, 49/167 Clinical neurology, 105/231 Neurosciencesspa
dc.identifier.citationGonzález-Freire, M., Santiago-Dorrego, C., Gómez-Gallego, F., Pérez-Ruiz, M., Foster, C., Arenas, J., & Lucía-Mulas, A. (2009). Does the K153R variant of the myostatin gene influence the clinical presentation of women with McArdle disease? Neuromuscular Disorders, 19(3), 220-222.spa
dc.identifier.doi10.1016/j.nmd.2009.01.001spa
dc.identifier.issn18732364spa
dc.identifier.urihttp://hdl.handle.net/11268/1120
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessen
dc.subject.otherGenetic Predisposition To Disease/*Geneticsspa
dc.subject.otherGlycogen Storage Disease Type V/*Geneticsspa
dc.subject.otherMutation/*Geneticsspa
dc.subject.otherMyostatin/*Geneticsspa
dc.subject.otherAmp Deaminase/Geneticsspa
dc.subject.otherDna Mutational Analysisspa
dc.subject.otherExercise Tolerance/Geneticsspa
dc.subject.otherFemalespa
dc.subject.otherGenetic Variation/Geneticsspa
dc.subject.otherGenotypespa
dc.subject.otherGlycogen/Metabolismspa
dc.subject.otherGlycogen Storage Disease Type V/Metabolismspa
dc.subject.otherGlycogen Storage Disease Type V/Physiopathologyspa
dc.subject.otherHeterozygotespa
dc.subject.otherHumansspa
dc.subject.otherMuscle Weakness/Geneticsspa
dc.subject.otherMuscle, Skeletal/Metabolismspa
dc.subject.otherMuscle, Skeletal/Physiopathologyspa
dc.subject.otherPeptidyl-Dipeptidase A/Geneticsspa
dc.subject.otherPhenotypespa
dc.subject.otherRespiratory Insufficiency/Geneticsspa
dc.subject.unescoEnfermedad nutricionalspa
dc.subject.unescoDeportespa
dc.subject.unescoTratamiento médicospa
dc.titleDoes the K153R variant of the myostatin gene influence the clinical presentation of women with McArdle disease?spa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublication747003ff-e813-4d18-861a-fe3db500ab6c
relation.isAuthorOfPublication8d71c009-8216-4d3f-bc9b-eb9b6443233c
relation.isAuthorOfPublicationa5c08444-aa82-4924-a71e-de56086bcd7c
relation.isAuthorOfPublicationd3691359-d7bd-4a12-b84e-338e28c81f9f
relation.isAuthorOfPublication.latestForDiscovery747003ff-e813-4d18-861a-fe3db500ab6c

Files